Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (ZBH) is a global innovator in musculoskeletal healthcare, delivering advanced orthopedic solutions for nearly a century. This news hub provides investors and medical professionals with timely updates on product developments, regulatory milestones, and strategic initiatives shaping the future of surgical care.
Track critical updates including quarterly earnings, FDA clearances for robotic surgery systems, and partnerships advancing AI-driven orthopedic solutions. Our curated feed consolidates press releases about joint reconstruction technologies, trauma care innovations, and global market expansions to inform your analysis of this medtech leader.
Discover how Zimmer Biomet’s integration of digital surgery platforms with traditional orthopedic expertise continues to redefine patient outcomes. Bookmark this page for direct access to verified updates about ZBH’s clinical advancements, without promotional commentary or speculative content.
Zimmer Biomet reported Q3 2021 net sales of $1.924 billion, a 0.3% decline from the prior year. Despite challenges, the company showed resilience with 1.7% growth from Q3 2019. Net earnings were $145.6 million, with an adjusted diluted EPS of $1.81. Key highlights include FDA clearance for Persona IQ, a smart knee implant, and the ROSA Hip System for robotic-assisted surgery. The company has updated its 2021 financial guidance, projecting reduced revenue growth of 11.3% - 12.5% and adjusted diluted EPS of $7.32 - $7.47.
Zimmer Biomet Holdings (NYSE: ZBH) announced that its Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will present at Stifel's 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 a.m. Eastern Time. Investors can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. Zimmer Biomet is a global leader in medical technology, focused on enhancing mobility and health through innovative products and technologies.
Zimmer Biomet Holdings, Inc. (ZBH) will host its third quarter earnings conference call on November 4, 2021, at 8:30 a.m. ET, with a news release available at 6:30 a.m. ET. The call can be accessed on the company’s Investor Relations website and will feature digital recording availability from November 4 to December 31, 2021. Zimmer Biomet is recognized for its innovative medical technology aimed at enhancing patient mobility and healthcare quality.
Zimmer Biomet Holdings (NYSE: ZBH) announced key leadership appointments for its planned spin-off company, ZimVie, targeting the Spine and Dental businesses. Richard J. Heppenstall joins as Executive Vice President and CFO, bringing over 25 years of finance experience in the medtech sector. The spin-off is on track for mid-2022, aiming to enhance resource allocation and market leadership. The new leadership team includes seasoned professionals across various functions to drive ZimVie’s success post-separation.
Zimmer Biomet Holdings has declared a quarterly cash dividend of $0.24 per share for the third quarter of 2021. This dividend will be payable on October 29, 2021 to shareholders on record as of September 30, 2021. The company, a leader in medical technology, is known for its innovative solutions aimed at improving health and mobility. Zimmer Biomet operates globally, contributing to advancements in patient care through integrated digital and robotic technologies.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced four presentations at the AAOS 2021 Annual Meeting showcasing the clinical value of mymobility with Apple Watch. This remote care management platform aids healthcare professionals in supporting patients pre- and post-orthopedic procedures. Initial findings from the ongoing mymobility Clinical Study suggest that patients using the platform experience similar outcomes to traditional care, potentially lowering postoperative costs. The conference is taking place from August 31 to September 3, 2021 in San Diego.
Zimmer Biomet Holdings (ZBH) announced that Chairman Bryan Hanson and CFO Suky Upadhyay will present at Baird's 2021 Virtual Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website. The company specializes in medical technology, focusing on enhancing patient mobility through innovative products and digital technologies. Zimmer Biomet operates in over 25 countries, with sales in more than 100 countries, and boasts over 90 years of industry experience.
Zimmer Biomet Holdings (NYSE: ZBH) has received FDA 510(k) clearance for its ROSA® Hip System, enhancing its robotic surgical portfolio. This system aids in robotically-assisted direct anterior total hip replacement, offering surgeons real-time data and control over surgical procedures. ROSA Hip integrates with ZBEdge and mymobility® technologies to improve patient outcomes and streamline surgical workflows. Designed for compatibility with various implant systems, it aims to enhance procedural efficiency and mitigate intra-operative variability.
Zimmer Biomet Holdings announced six key data presentations at the upcoming American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting scheduled for August 31 to September 3 in San Diego. Highlights include a podium presentation of the investigational Persona IQ smart knee implant and three posters detailing the clinical utility of the mymobility remote care management platform. The company is set to showcase its latest technologies, including the ROSA Hip, which is currently under FDA review, as part of its ZBEdge Connected Intelligence suite.
Zimmer Biomet Holdings reported second-quarter 2021 net sales of $2.027 billion, a remarkable 65.3% increase from the previous year. Net earnings reached $141.9 million ($0.67 per share) with adjusted diluted EPS at $1.90. Compared to pre-pandemic Q2 2019, sales are up 1.9%. The company anticipates continued growth despite ongoing COVID-19 pressures. Zimmer Biomet has also updated its full-year 2021 guidance, projecting revenue growth of 14.5% - 16.5% and adjusted diluted EPS of $7.65 - $7.95.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
